PRFN

Perfect Holding SA, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics for the treatment of viral, respiratory, and ophthalmic diseases. Its therapeutic drug candidate is KIN001, an advanced clinical stage p38 MAPK inhibitor combined with a marketed drug together enabling an oral long-term treatment for patients suffering from diseases. The company is based in Lausanne, Switzerland.